Novavax Inc (NVAX) outlines its strategic focus on partnerships and pipeline expansion while navigating revenue fluctuations ...

Sanofi India share price gained up to 6% in morning trades on Friday post Q4 results announced by the company after the ...

Commercial Launch Preparations Advancing Prior to September 26 PDUFA Date; Regulatory Filings Under Review in U.S., Europe and ChinaTopline ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

An FDA vaccine advisory committee meeting to discuss next season’s flu vaccine has been canceled, potentially delaying the ...

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...

An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...

Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...